US 12310965
Treatment of cancer utilizing an identified adenosine fingerprint
granted A61KA61K31/506A61K31/706
Quick answer
US patent 12310965 (Treatment of cancer utilizing an identified adenosine fingerprint) held by Arcus Biosciences, Inc. expires Mon May 22 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Arcus Biosciences, Inc.
- Grant date
- Tue May 27 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon May 22 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 8
- CPC classes
- A61K, A61K31/506, A61K31/706, A61K31/7076, A61K45/06